1. This study evaluated the effects of lacosamide (LCM) monotherapy on sleep architecture in patients with focal epilepsy.
2. Results showed a significant decrease in seizure frequency, an increase in sleep efficiency, and a decrease in sleep latency and wakefulness after sleep onset.
3. The study suggests that LCM monotherapy may positively impact sleep architecture in patients with epilepsy.
The article is generally reliable and trustworthy, as it provides evidence from a study conducted to evaluate the effects of lacosamide (LCM) monotherapy on sleep architecture in patients with focal epilepsy. The study was conducted using polysomnography at baseline and at the 6-month follow-up visit, which is a reliable method for assessing sleep architecture. Furthermore, the results of the study are presented clearly and objectively, providing evidence for the positive effects of LCM monotherapy on sleep architecture.
However, there are some potential biases that should be noted when considering this article. Firstly, the sample size used for this study was relatively small (10 participants), which could limit its generalizability to larger populations. Additionally, there is no mention of any potential side effects or risks associated with taking LCM monotherapy, which should be taken into consideration when evaluating its efficacy as a treatment option for epilepsy patients. Finally, there is no discussion of any alternative treatments or therapies that could be used to improve sleep architecture in these patients; thus, further research should explore other options that may be available to them.